技术-组织-环境框架下知识优势对医药制造业创新绩效的组态分析  

Research on antecedent configuration of knowledge advantages for innovative performance of pharmaceutical manufacturing industry under technology-organization-environment framework

作　　者：朱旺旺 陶群山 陶世奇 付芮 ZHU Wang-wang;TAO Qun-shan;TAO Shi-qi;FU Rui(School of Medical Economics and Management,Anhui University of Traditional Chinese Medicine,Hefei 230012,China;Key Laboratory of Data Science and Innovation and Development of Traditional Chinese Medicine,Hefei 230012,China)

机构地区：[1]安徽中医药大学医药经济管理学院,合肥230012 [2]数据科学与中医药创新发展安徽省哲学社会科学重点实验室,合肥230012

出　　处：《中国新药杂志》2024年第10期961-970,共10页Chinese Journal of New Drugs

基　　金：安徽省高校优青重点项目(gxyqZD2021015);教育部人文项目(18YJA630103);安徽省高校协同创新项目(GXXT-2022-095)。

摘　　要：基于技术-组织-环境(TOE)框架,以我国31个省份为研究案例,运用模糊集定性比较分析(fsQCA)方法从知识优势形成角度分析技术、组织、环境等条件对提升我国医药制造业创新绩效的联动效应及驱动路径。结果表明,单一知识优势并不是导致高水平医药制造业创新绩效的必要条件,知识优势对医药制造业创新绩效影响存在多重并发因果关系,产生3条高水平医药制造业创新绩效的组态。以技术创新能力、组织运营规模和政府支持力度为核心条件,将3条组态分为2种路径,即“技术-环境”双元驱动型路径和“技术-组织-环境”三元协同型路径;知识优势驱动医药制造业创新绩效的高水平组态存在地区差异。建议政府、医药行业及企业重视并强化不同要素组合的深度融合和联动效应,因地制宜、因需施策,从而使医药制造业建立并发挥知识优势以提高创新绩效。Based on the technology-organization-environment(TOE)framework and taking 31 provinces in China as cases,the fuzzy set qualitative comparative analysis(fsQCA)method was used to analyze the linkage effect and driving path of technological,organizational,and environmental conditions on improving the innovation performance of China's pharmaceutical manufacturing industry from the perspective of knowledge advantage formation.The results indicated that a single knowledge advantage is not a necessary condition for leading to high-level innovation performance in the pharmaceutical manufacturing industry.The impact of knowledge advantage on the innovation performance of the pharmaceutical manufacturing industry has multiple concurrent causal relationships,resulting in three configurations of high-level pharmaceutical manufacturing industry innovation performance.Based on the core conditions of technological innovation capability,organizational operation scale,and government support,the three configurations are divided into two paths,namely the dual driven path of“technology environment”and the collaborative path of“technology organization environment”.There are regional dfferences in the high-level configuration of knowledge advantages driving innovation performance in the pharmaceutical manufacturing industry.It is recommended that the government,pharmaceutical industry,and enterprises attach importance to and strengthen the deep integration.

关 键 词：医药制造业 创新绩效 技术-组织-环境框架 知识优势 

分 类 号：R95[医药卫生—药学]